One investment company can proceed with most of its counterclaims against another for a dispute in a biomedical securities transaction, the Court of Chancery ruled Thursday.

But Judge Paul R. Wallace wrote for the Court of Chancery that the tribunal lacks jurisdiction over one breach-of-contract claim brought by Casla Bio Holdings and Casla Bio GP LLC against CLP Toxicology Inc. because it involved what financial information should be considered when calculating a contingent payment.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]